Nkarta, Inc.
NASDAQ: NKTXSouth San Francisco, US · Founded 2015 · 160 employees on LinkedIn · 4 known investors
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Founders & leadership
Board
MD
Michael DybbsBoard director
JC
Jill CarrollBoard director
TA
Tiba AynechiBoard director
FA
Fouad AzzamBoard director
AB
Ali BehbahaniBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$43.9M disclosed across 1 round · 2019
▶$43.9MraisedSep 2019 · 13 investors · BiotechnologyRule 506(b)
▶$43.9MraisedSep 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew PlunkettExecutive Officer
- Michael DybbsDirector
- Jill CarrollDirector
- Tiba AynechiDirector
- Paul HastingsExecutive Officer, Director
- Fouad AzzamDirector
- Ali BehbahaniDirector
- Offering amount
- $114.6M
- Amount sold
- $43.9M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Nektar Therapeutics23 shared keywordsNektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.
Seeking Alpha18 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood18 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Nkarta, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nkarta, Inc. do?
- Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
- Who are Nkarta, Inc.'s investors?
- Nkarta, Inc.'s investors include New Enterprise Associates (NEA), Samsara BioCapital, SR One Capital Management, Norwest Venture Partners.
- How much funding has Nkarta, Inc. raised?
- Nkarta, Inc. has disclosed $43.9M raised across 1 round.
- Where is Nkarta, Inc. headquartered?
- Nkarta, Inc. is headquartered in South San Francisco, US.